0

Pharmacogenomics Market by End-user and Geography - Forecast and Analysis 2022-2026

  • Published: Sep 2022
  • Pages: 124
  • SKU: IRTNTR74299
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The pharmacogenomics market share is expected to increase by USD 2.50 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 6.93%.

This pharmacogenomics market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers pharmacogenomics market segmentation by end-user (hospitals and clinics, research organizations, and academics) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The pharmacogenomics market report also offers information on several market vendors, including 23andMe Inc., Abbott Laboratories, Admera Health, and ATS GENETECH PVT. LTD., Dynamic DNA Laboratories, geneOmbio Technologies Pvt. Ltd., Illumina Inc., Laboratory Corp. of America Holdings, Mesa Labs Inc., Myriad Genetics Inc., OneOme LLC, OPKO Health Inc., QIAGEN NV, Quest Diagnostics Inc., and Thermo Fisher Scientific Inc. among others.

What will the Pharmacogenomics Market Size be During the Forecast Period?

Pharmacogenomics Market Size

Download Report Sample to Unlock the Pharmacogenomics Market Size for the Forecast Period and Other Important Statistics

 

Pharmacogenomics Market: Key Drivers, Trends, and Challenges

The rising prevalence of genetic diseases and disorders is notably driving the pharmacogenomics market growth, although factors such as varying regulations on pharmacogenomics testing and research globally may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic's impact on the pharmacogenomics industry. The holistic analysis of the drivers will help deduce end goals and refine marketing strategies to gain a competitive edge.

Key Pharmacogenomics Market Driver

The rising prevalence of genetic diseases and disorders is one of the major drivers impacting the pharmacogenomics market growth. The significant demand for genetic testing products is attributed to prenatal genetic testing procedures. The increasing incidence of disabilities in newborns has increased the adoption of prenatal testing for the timely treatment of manageable genetic disorders and diseases. For instance, according to the CDC, 1 in every 33 babies (about 3%) is born with birth defects in the US every year. Similarly, between 7 million and 9 million babies are born with birth defects globally. Moreover, early disease diagnosis through prenatal testing procedures is largely preferred by parents with inheritable genetic conditions such as autosomal dominant and recessive disorders. For instance, either parent having a gene with an autosomal dominant condition has a 50% chance of inheriting the disorder to their offspring. This creates a necessity among parents to opt for preventive diagnostic procedures such as prenatal genetic testing. 

Key Pharmacogenomics Market Trend

The growing adoption of direct-to-consumer genetic tests in early disease diagnosis is one of the major trends influencing the pharmacogenomics market growth. Growing demand for timely initiation of healthcare treatments and the increasing adoption of preventive approaches for avoiding disease risks have increased the use of direct-to-consumer genetic tests globally. Market vendors such as Quest Diagnostics, Myriad Genetics Inc., and 23andMe Inc. are offering direct-to-consumer pharmacogenomic testing products such as non-invasive DNA tests, which are designed to assess the risks of developing common health conditions such as migraine, autoimmune disorders, lupus, Alzheimer's disease, melanoma, lung cancer, cystic fibrosis, bladder cancer, colorectal cancer, and breast cancer. 

Key Pharmacogenomics Market Challenge

Varying regulations on pharmacogenomics testing and research globally are one of the major challenges impeding the pharmacogenomics market growth. PCR kits and assays used for in vitro pharmacogenomics testing are regulated under the FDA's 21 CFR (Code of Federal Regulations) in the US, whereas the EU IVD Directive (98/79/EC) regulates the use of PCR kits and assays for in vitro testing in Europe. In addition, clinical laboratories using these assays are required to comply with the regulatory requirements related to clinical and analytical validation in sequencing workflow. Results provided to patients by these clinical laboratories are subjected to legal obligations related to the reproducibility of test results and adherence to high standards of specificity and sensitivity. These results need to meet varying compliance requirements of authorities such as the Centers for Medicare and Medicaid Services (CMS) and Clinical Laboratory Improvement Amendments (CLIA) in the US and the EMA in Europe. Such variations in standards among regulatory authorities hinder compliance, thereby threatening the swift business operations of market vendors across countries. Owing to these factors, the global pharmacogenomics market is expected to witness significant growth during the forecast period.

This pharmacogenomics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global pharmacogenomics market as a part of the global life science tools and services market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the pharmacogenomics market during the forecast period.

Who are the Major Pharmacogenomics Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • 23andMe Inc.
  • Abbott Laboratories
  • Admera Health
  • ATS GENETECH PVT. LTD.
  • Dynamic DNA Laboratories
  • geneOmbio Technologies Pvt. Ltd.
  • Illumina Inc.
  • Laboratory Corp. of America Holdings
  • Mesa Labs Inc.
  • Myriad Genetics Inc.
  • OneOme LLC
  • OPKO Health Inc.
  • QIAGEN NV
  • Quest Diagnostics Inc.
  • Thermo Fisher Scientific Inc.

 

This statistical study of the pharmacogenomics market encompasses successful business strategies deployed by the key vendors. The pharmacogenomics market is concentrated and the vendors are deploying organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The pharmacogenomics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the leading companies' production, sustainability, and prospects.

Pharmacogenomics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the pharmacogenomics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Pharmacogenomics Market?

Pharmacogenomics Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

39% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for the pharmacogenomics market in North America. Market growth in this region will be faster than the growth of the market in other regions.

Growing concerns about early disease diagnosis, a significant rise in commercial approvals for advanced pharmacogenomics products, and the increasing use of pharmacogenomic testing will facilitate the pharmacogenomics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020 and 2021, the COVID-19 outbreak increased the demand for pharmacogenomics, as PCR tests were performed to identify the presence of the virus in the vulnerable population. However, owing to a decline in visits to diagnostic labs and hospitals due to the imposition of a stay-at-home policy, the demand for pharmacogenomics for other chronic illnesses declined in the first half of 2021. 

What are the Revenue-generating End-user Segments in the Pharmacogenomics Market?

Pharmacogenomics Market Share

To gain further insights on the market contribution of various segments Request a PDF Sample

The pharmacogenomics market share growth in the hospitals and clinics segment will be significant during the forecast period. The rising awareness of early disease diagnosis has created a shift from responsive to preventive care practices. This has increased the demand for predictive diagnostic testing among individuals.

This report provides an accurate prediction of the contribution of all the segments to the growth of the pharmacogenomics market size and actionable market insights on the post-COVID-19 impact on each segment.

 

Pharmacogenomics Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 6.93%

Market growth 2022-2026

$2.50 billion

Market structure

Concentrated

YoY growth (%)

6.11

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 39%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

23andMe Inc., Abbott Laboratories, Admera Health, ATS GENETECH PVT. LTD., Dynamic DNA Laboratories, geneOmbio Technologies Pvt. Ltd., Illumina Inc., Laboratory Corp. of America Holdings, Mesa Labs Inc., Myriad Genetics Inc., OneOme LLC, OPKO Health Inc., QIAGEN NV, Quest Diagnostics Inc., and Thermo Fisher Scientific Inc. 

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Pharmacogenomics Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive pharmacogenomics market growth during the next five years
  • Precise estimation of the pharmacogenomics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the pharmacogenomics industry across North America, Europe, Asia, and the Rest of the World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of pharmacogenomics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by End-user

    • 5.1 Market segments
      • Exhibit 24: Chart on End-user - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on End-user - Market share 2021-2026 (%)
    • 5.2 Comparison by End-user
      • Exhibit 26: Chart on Comparison by End-user
      • Exhibit 27: Data Table on Comparison by End-user
    • 5.3 Hospitals and clinics - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Hospitals and clinics - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Hospitals and clinics - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Hospitals and clinics - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Hospitals and clinics - Year-over-year growth 2021-2026 (%)
    • 5.4 Research organizations - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Research organizations - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Research organizations - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Research organizations - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Research organizations - Year-over-year growth 2021-2026 (%)
    • 5.5 Academic - Market size and forecast 2021-2026
      • Exhibit 36: Chart on Academic - Market size and forecast 2021-2026 ($ million)
      • Exhibit 37: Data Table on Academic - Market size and forecast 2021-2026 ($ million)
      • Exhibit 38: Chart on Academic - Year-over-year growth 2021-2026 (%)
      • Exhibit 39: Data Table on Academic - Year-over-year growth 2021-2026 (%)
    • 5.6 Market opportunity by End-user
      • Exhibit 40: Market opportunity by End-user ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 42: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 44: Chart on Geographic comparison
      • Exhibit 45: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Germany - Market size and forecast 2021-2026
      • Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.9 Canada - Market size and forecast 2021-2026
      • Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.10 UK - Market size and forecast 2021-2026
      • Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.11 China - Market size and forecast 2021-2026
      • Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 82: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 83: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 85: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 86: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 87: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 88: Matrix on vendor position and classification
            • 10.3 23andMe Inc.
              • Exhibit 89: 23andMe Inc. - Overview
              • Exhibit 90: 23andMe Inc. - Product / Service
              • Exhibit 91: 23andMe Inc. - Key offerings
            • 10.4 Abbott Laboratories
              • Exhibit 92: Abbott Laboratories - Overview
              • Exhibit 93: Abbott Laboratories - Business segments
              • Exhibit 94: Abbott Laboratories - Key news
              • Exhibit 95: Abbott Laboratories - Key offerings
              • Exhibit 96: Abbott Laboratories - Segment focus
            • 10.5 Admera Health
              • Exhibit 97: Admera Health - Overview
              • Exhibit 98: Admera Health - Product / Service
              • Exhibit 99: Admera Health - Key offerings
            • 10.6 ATS GENETECH PVT. LTD.
              • Exhibit 100: ATS GENETECH PVT. LTD. - Overview
              • Exhibit 101: ATS GENETECH PVT. LTD. - Product / Service
              • Exhibit 102: ATS GENETECH PVT. LTD. - Key offerings
            • 10.7 Dynamic DNA Laboratories
              • Exhibit 103: Dynamic DNA Laboratories - Overview
              • Exhibit 104: Dynamic DNA Laboratories - Product / Service
              • Exhibit 105: Dynamic DNA Laboratories - Key offerings
            • 10.8 geneOmbio Technologies Pvt. Ltd.
              • Exhibit 106: geneOmbio Technologies Pvt. Ltd. - Overview
              • Exhibit 107: geneOmbio Technologies Pvt. Ltd. - Product / Service
              • Exhibit 108: geneOmbio Technologies Pvt. Ltd. - Key offerings
            • 10.9 Mesa Labs Inc.
              • Exhibit 109: Mesa Labs Inc. - Overview
              • Exhibit 110: Mesa Labs Inc. - Business segments
              • Exhibit 111: Mesa Labs Inc. - Key offerings
              • Exhibit 112: Mesa Labs Inc. - Segment focus
            • 10.10 Myriad Genetics Inc.
              • Exhibit 113: Myriad Genetics Inc. - Overview
              • Exhibit 114: Myriad Genetics Inc. - Product / Service
              • Exhibit 115: Myriad Genetics Inc. - Key offerings
            • 10.11 OneOme LLC
              • Exhibit 116: OneOme LLC - Overview
              • Exhibit 117: OneOme LLC - Product / Service
              • Exhibit 118: OneOme LLC - Key offerings
            • 10.12 Thermo Fisher Scientific Inc.
              • Exhibit 119: Thermo Fisher Scientific Inc. - Overview
              • Exhibit 120: Thermo Fisher Scientific Inc. - Business segments
              • Exhibit 121: Thermo Fisher Scientific Inc. - Key news
              • Exhibit 122: Thermo Fisher Scientific Inc. - Key offerings
              • Exhibit 123: Thermo Fisher Scientific Inc. - Segment focus

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 124: Inclusions checklist
                • Exhibit 125: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 126: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 127: Research methodology
                • Exhibit 128: Validation techniques employed for market sizing
                • Exhibit 129: Information sources
              • 11.5 List of abbreviations
                • Exhibit 130: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Pharmacogenomics market growth will increase by $2503.63 million during 2022-2026.
              The pharmacogenomics market is expected to grow at a CAGR of 6.93% during 2022-2026.
              Technavio has segmented the pharmacogenomics market by geographic (North America, Europe, Asia, and Rest of World (ROW)).
              23andMe Inc., Abbott Laboratories, Admera Health, ATS GENETECH PVT. LTD., Dynamic DNA Laboratories, geneOmbio Technologies Pvt. Ltd., Illumina Inc., Laboratory Corp. of America Holdings, Mesa Labs Inc., Myriad Genetics Inc., OneOme LLC, OPKO Health Inc., QIAGEN NV, Quest Diagnostics Inc., Thermo Fisher Scientific Inc. are a few of the key vendors in the pharmacogenomics market.
              North America will register the highest growth rate of 39.3% among the other regions. Therefore, the pharmacogenomics market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the pharmacogenomics market growth are:
              • Rising prevalence of genetic diseases and disorders
              • Growing adoption of direct-to-consumer genetic tests in early disease diagnosis
              The pharmacogenomics market vendors should focus on grabbing business opportunities from the segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>